RT @ElizSMcKenna: ICYMI in @CD_AACR, relevant to comments just made by Gordon Freeman at #KCRS22: Design and Efficacy of a Monovalent Bispe…

RT @ElizSMcKenna: ICYMI in @CD_AACR, relevant to comments just made by Gordon Freeman at #KCRS22: Design and Efficacy of a Monovalent Bispe…

ICYMI in @CD_AACR, relevant to comments just made by Gordon Freeman at #KCRS22: Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells https://t.co/XqyrluGpcZ https://t.co/wZ7TxVG00H

@AlbigesL gives an update on the first-in-human study of MEDI5752 at the #ASCO22 Bispecifics Clinical Science Symposium - read more on MEDI5752 in @CD_AACR: https://t.co/XqyrluGpcZ https://t.co/xIwokOuhcJ

RT @ElizSMcKenna: I'm looking forward to the phase I update on the PD-1/CTLA-4 bispecific antibody MEDI5752 at today's #AACR22 Clinical Tri…

RT @ElizSMcKenna: I'm looking forward to the phase I update on the PD-1/CTLA-4 bispecific antibody MEDI5752 at today's #AACR22 Clinical Tri…

RT @ElizSMcKenna: I'm looking forward to the phase I update on the PD-1/CTLA-4 bispecific antibody MEDI5752 at today's #AACR22 Clinical Tri…

I'm looking forward to the phase I update on the PD-1/CTLA-4 bispecific antibody MEDI5752 at today's #AACR22 Clinical Trials Plenary Session - you can read the initial characterization of MEDI5752 w/some early clinical results in @CD_AACR: https://t.co/Xqy

RT @rio_sugimura: Today's read 115 #CancerImmunology @CD_AACR Design and Efficacy of a Monovalent #Bispecific #PD-1/#CTLA4 #Antibody That…

Today's read 115 #CancerImmunology @CD_AACR Design and Efficacy of a Monovalent #Bispecific #PD-1/#CTLA4 #Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells | Cancer Discovery https://t.co/jhgUEF48oI

RT @CD_AACR: From the May issue: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1…

RT @CD_AACR: From the May issue: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1…

RT @CD_AACR: From the May issue: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1…

RT @CD_AACR: From the May issue: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1…

From the May issue: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells. @SJDovedi @AstraZeneca #immunotherapy https://t.co/gPQgvcp2ub https://t.co/iptKmvbVTB

RT @imsmd: Watching the #AACR21 T-Cell Redirection and Costimulation Using Engineered Bispecific Antibodies session? Check out the recent @…

RT @imsmd: Watching the #AACR21 T-Cell Redirection and Costimulation Using Engineered Bispecific Antibodies session? Check out the recent @…

Watching the #AACR21 T-Cell Redirection and Costimulation Using Engineered Bispecific Antibodies session? Check out the recent @CD_AACR paper describing the bispecific PD-1/CTLA-4 MEDI5752 by @SJDovedi @Oncology_at_AZ @astrazeneca and colleagues https://t.

RT @SyedAAhmad5: Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells…

Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells ⁦@CD_AACR⁩ @swog https://t.co/i75FzSIfhX

RT @NatRevClinOncol: MEDI5752, a bispecific anti-PD-1/CTLA4 antibody preferentially saturates CTLA4 on PD-1+ vs PD-1− T cells, reducing the…

RT @NatRevClinOncol: MEDI5752, a bispecific anti-PD-1/CTLA4 antibody preferentially saturates CTLA4 on PD-1+ vs PD-1− T cells, reducing the…

RT @NatRevClinOncol: MEDI5752, a bispecific anti-PD-1/CTLA4 antibody preferentially saturates CTLA4 on PD-1+ vs PD-1− T cells, reducing the…

RT @NatRevClinOncol: MEDI5752, a bispecific anti-PD-1/CTLA4 antibody preferentially saturates CTLA4 on PD-1+ vs PD-1− T cells, reducing the…

RT @NatRevClinOncol: MEDI5752, a bispecific anti-PD-1/CTLA4 antibody preferentially saturates CTLA4 on PD-1+ vs PD-1− T cells, reducing the…

RT @NatRevClinOncol: MEDI5752, a bispecific anti-PD-1/CTLA4 antibody preferentially saturates CTLA4 on PD-1+ vs PD-1− T cells, reducing the…

MEDI5752, a bispecific anti-PD-1/CTLA4 antibody preferentially saturates CTLA4 on PD-1+ vs PD-1− T cells, reducing the dose required for IL-2 secretion, leading to the rapid internalization & degradation of PD-1. PRs were observed in two patients: http

RT @CD_AACR: ICYMI: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T…

ICYMI: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells. @SJDovedi @AstraZeneca #immunotherapy https://t.co/uqcxVPmSLp https://t.co/Cd2I9Y0ZqN

RT @_Mr_Coyote: Est ce que Genoway vient de confirmer une bombe? -Totalement Est ce que le marché s’en tape complet? -Complètement https:…

RT @genOway_SA: #AstraZeneca develops a new monovalent bispecific PD-1/CTLA-4 antibody with reduced autoimmune side effects by taking advan…

GENE GO AWAY ? OR GENE IS AWARE ?

Est ce que Genoway vient de confirmer une bombe? -Totalement Est ce que le marché s’en tape complet? -Complètement https://t.co/RzRNJaZCSJ

RT @genOway_SA: #AstraZeneca develops a new monovalent bispecific PD-1/CTLA-4 antibody with reduced autoimmune side effects by taking advan…

RT @genOway_SA: #AstraZeneca develops a new monovalent bispecific PD-1/CTLA-4 antibody with reduced autoimmune side effects by taking advan…

RT @Groumie_: $ALGEN 👇

RT @ActionManNews: #Genoway @inchi232

RT @genOway_SA: #AstraZeneca develops a new monovalent bispecific PD-1/CTLA-4 antibody with reduced autoimmune side effects by taking advan…

RT @genOway_SA: #AstraZeneca develops a new monovalent bispecific PD-1/CTLA-4 antibody with reduced autoimmune side effects by taking advan…

RT @genOway_SA: #AstraZeneca develops a new monovalent bispecific PD-1/CTLA-4 antibody with reduced autoimmune side effects by taking advan…

#Genoway @inchi232

$ALGEN 👇

#AstraZeneca develops a new monovalent bispecific PD-1/CTLA-4 antibody with reduced autoimmune side effects by taking advantage of our double-humanized PD-1/CTLA-4 mouse model. Read the paper 👉 https://t.co/LoCGXGDU0N #immunotherapy #oncology #immunology h

น่าจับตามองมาก https://t.co/X7DUyeUqqu

RT @NatRevClinOncol: Study reports the design and initial efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blo…

RT @weldeiry: Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells…

RT @NatRevClinOncol: Study reports the design and initial efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blo…

Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells | Cancer Discovery https://t.co/5bEJIB2XMk

RT @NatRevClinOncol: Study reports the design and initial efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blo…

A novel checkpoint inhibitor. Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells https://t.co/LB4GgbN00b

Study reports the design and initial efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells; PRs were observed in 2 pts with advanced solid tumours: https://t.co/XcWUgK94bs #ImmunoOnc #caxtx

Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells https://t.co/27dfhr878i

Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells. https://t.co/t7vDz1FLVN https://t.co/31Qfk6FEd6

https://t.co/k1rUPTK9W3

RT @SHasani410: Excited to share my contributions to a novel biologic during my time at Medimmune (currently AZ)! Our team engineered a mon…

RT @CD_AACR: Just published #OnlineFirst: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockad…

RT @CD_AACR: Just published #OnlineFirst: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockad…

RT @CD_AACR: Just published #OnlineFirst: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockad…

Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells https://t.co/EFAgypyqAg

Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells https://t.co/htgvlqC25B

RT @SHasani410: Excited to share my contributions to a novel biologic during my time at Medimmune (currently AZ)! Our team engineered a mon…

RT @CD_AACR: Just published #OnlineFirst: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockad…

Thrilled and honored to have been a part of this initiative!

Just published #OnlineFirst: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells. @SJDovedi @AstraZeneca #immunotherapy https://t.co/V2cxXmHz7l https://t.co/wRPDrYdhqv

Excited to share my contributions to a novel biologic during my time at Medimmune (currently AZ)! Our team engineered a monovalent bispecific antibody enhancing T-Cell checkpoint blockade in the tumor microenvironment. Check it out at @CD_AACR @AACR 1/8 h

Now online in @CD_AACR: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells @SJDovedi @AstraZeneca #immunotherapy https://t.co/cj24toc11v